CareDx, Inc Stock

Equities

CDNA

US14167L1035

Biotechnology & Medical Research

Delayed Nasdaq 03:54:20 2024-04-18 pm EDT 5-day change 1st Jan Change
8.145 USD -1.63% Intraday chart for CareDx, Inc -10.67% -31.96%
Sales 2024 * 267M Sales 2025 * 287M Capitalization 429M
Net income 2024 * -80M Net income 2025 * -64M EV / Sales 2024 * 1.51 x
Net cash position 2024 * 24.45M Net Debt 2025 * 1.1M EV / Sales 2025 * 1.5 x
P/E ratio 2024 *
-5.5 x
P/E ratio 2025 *
-7.04 x
Employees 639
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.25%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.48%
1 week-10.58%
Current month-21.81%
1 month-18.34%
3 months-16.70%
6 months+43.25%
Current year-31.00%
More quotes
1 week
7.84
Extreme 7.84
9.14
1 month
7.84
Extreme 7.84
11.10
Current year
7.83
Extreme 7.83
12.83
1 year
4.80
Extreme 4.8
12.93
3 years
4.80
Extreme 4.8
96.88
5 years
4.80
Extreme 4.8
99.83
10 years
0.76
Extreme 0.76
99.83
More quotes
Managers TitleAgeSince
Director of Finance/CFO 48 21-07-31
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 66 15-03-01
Director/Board Member 68 14-04-07
Director/Board Member 72 19-08-26
More insiders
Date Price Change Volume
24-04-18 8.145 -1.63% 361 335
24-04-17 8.28 +5.48% 2,009,569
24-04-16 7.85 -4.27% 489,996
24-04-15 8.2 -3.87% 609,502
24-04-12 8.53 -6.67% 726,175

Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT

More quotes
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
8.28 USD
Average target price
12.5 USD
Spread / Average Target
+50.97%
Consensus